Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE. de Jong PH, et al. Among authors: de jager mh, de sonnaville pb. Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. doi: 10.1093/rheumatology/kew321. Epub 2016 Aug 30. Rheumatology (Oxford). 2016. PMID: 27581208 Clinical Trial.
Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.
de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, Luime JJ, Weel AE. de Jong PH, et al. Among authors: de jager mh, de sonnaville pb. Rheumatology (Oxford). 2012 Jul;51(7):1269-77. doi: 10.1093/rheumatology/kes008. Epub 2012 Feb 29. Rheumatology (Oxford). 2012. PMID: 22378716 Clinical Trial.
Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis.
de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Ćalasan MB, Weel AE, Huisman AM, Gerards AH, van Schaeybroeck B, Wulffraat NM, Lindemans J, Hazes JM, de Jonge R. de Rotte MC, et al. Among authors: de jonge r, de jong ph. Ann Rheum Dis. 2015 Feb;74(2):408-14. doi: 10.1136/annrheumdis-2013-203725. Epub 2013 Dec 2. Ann Rheum Dis. 2015. PMID: 24297383
Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.
Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ. Teitsma XM, et al. Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14. Ann Rheum Dis. 2018. PMID: 29760159 Clinical Trial.
Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.
Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG. Teitsma XM, et al. Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. Ann Rheum Dis. 2019. PMID: 30158123 No abstract available.
80 results